Wegovy results after 1 month: what actually happens

Step 1: what month one is actually for (it is not the peak)

Wegovy's dosing schedule starts at 0.25 mg once weekly. That first month is a settling-in period, its job is to let your body adapt to the medicine, not to deliver the largest possible weight reduction right away. The prescriber-led titration then moves through 0.5 mg, 1.0 mg and 1.7 mg before reaching 2.4 mg at around week 17 for most people.

This matters for expectations. People who feel discouraged at week four because the number on the scales has not shifted dramatically are often comparing themselves to trial averages taken over 68 weeks, not four. The NHS patient information for semaglutide describes this step-up schedule clearly, and our clinical team at nume (sorry, at nume) reviews each patient's progress before any dose change is made.

What you may notice in month one: food feels less urgent. Many people report eating smaller portions without deliberately trying to, or leaving food on the plate for the first time in years. That appetite shift is not a placebo, it reflects semaglutide's action on GLP-1 receptors involved in hunger signalling. If you want to understand the mechanism behind those early changes, the Wegovy overview covers it in detail.

Practical note: your pen arrives in plain, unbranded packaging via DPD tracked delivery. The KwikPen itself is pre-loaded; you rotate injection sites across the abdomen, thigh or upper arm each week, using a fresh needle.

Step 2: putting the 1-month figure in context of the full trajectory

The STEP 1 trial followed 1,961 adults without diabetes over 68 weeks. Average weight loss reached roughly 15% of starting body weight at 2.4 mg maintenance, a figure widely cited as the benchmark for semaglutide's effectiveness. Month one contributes a small fraction of that total.

A realistic picture across the first year tends to look something like this: modest loss in months one and two while doses are low; more pronounced loss through months three to six as the maintenance dose takes hold; continued, often slower, loss in the second half of the year. Three-month results and six-month results give a clearer picture of where the trajectory tends to go, and reading about what wegovy 4 month results typically look like can help you understand the dose-change milestone that falls around that point.

Individual variation is real. Starting weight, activity level, dietary habits and how consistently the injection schedule is followed all influence pace. The trial's 15% average means some participants lost more, some considerably less. A prescriber, not a general average, is the right guide for what progress looks like for you specifically.

For people considering whether Wegovy is the right option at all, the weight-loss treatment overview sets out what the licensed options are and how they differ.

Step 3: side effects in month one and what to do about them

The most common complaints in the first four weeks are gastrointestinal: nausea, loose stools, constipation, reflux or a general feeling of fullness that tips into discomfort. These are well-documented, typically mild to moderate, and for most people they ease within a few weeks as the body acclimatises to the starter dose.

A few practical things that tend to help: eating slowly, keeping meals smaller, avoiding very fatty or heavily processed food, and staying well hydrated. None of these replace your prescriber's or pharmacist's advice, they are simply the patterns that come up repeatedly in clinical practice.

More serious symptoms require prompt medical attention. Severe abdominal pain, particularly pain that travels through to the back, is something to take seriously and seek help for without delay. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines. You can report any suspected side effect directly through the Yellow Card scheme.

Injection-site reactions (redness, mild swelling) are also possible. Rotating sites each week reduces the likelihood of localised skin changes. If you have questions about what you are experiencing, our support team is available seven days a week.

Step 4: when to reassess and what happens next

NICE guidance on semaglutide (Wegovy) recommends reviewing progress at six months on the maintenance dose. If weight loss at that point is less than 5% of starting body weight, continuing may not be appropriate, that decision sits with your prescriber, made in the context of your full clinical picture, not a formula.

Month one is not that review point. It is the starting line, not the finishing post. People who see very little on the scales at week four and stop treatment early often do so before the dose has reached a level where meaningful effect is expected. How long Wegovy takes to work goes into more depth on the timeline question.

If you are thinking about what comes after month one, month two and month four both sit at dose-change points for many people, worth reading before your next clinical review. And for anyone still deciding whether to start, speaking to our prescribers is the first step: the consultation is free, reviewed the same day by a GPhC-registered clinician, and comes with no obligation.